Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Imfinzi (durvalumab) has been cleared by the US regulator for the treatment of adult patients with locally advanced or metastatic BTC in combination with gemcitabine/cisplatin chemotherapy ...

AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...

AstraZeneca AZN announced that CHMP has recommended approval for its blockbuster cancer drug Imfinzi (durvalumab) as a monotherapy for treating limited-stage small cell lung cancer (LS-SCLC ...

on Wednesday provided an update on its Phase 1b/2 DURIPANC clinical trial evaluating the combination of Ampligen or rintatolimod and Imfinzi or durvalumab in treating late-stage pancreatic cancer.

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...